CREATE Medicines Raises $122 Million Series B to Advance In Vivo CAR-T Programs in Autoimmune Disease and Oncology

May 14, 2026-

CREATE Medicines announced the closing of a $122 million Series B financing to advance its pipeline of in vivo immune programming therapies across autoimmune disease and oncology. The round was co-led by existing investors Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners, with participation from Alexandria Venture Investments and other current investors.

The financing will support the clinical advancement of CREATE’s repeat-dose capable CD19-targeted in vivo CAR-T therapy for autoimmune disease, expansion of its dual CAR CD19 x BCMA program, and continued progress across its oncology portfolio. CREATE’s platform uses mRNA-LNP technology to program immune cells directly inside the body, avoiding the complex ex vivo cell collection, engineering, expansion, and reinfusion steps required by conventional CAR-T therapies.

CREATE stated that it has dosed more than 50 patients across its in vivo CAR clinical programs, describing this as the largest clinical dataset in the field. The company believes this growing translational experience provides an important foundation for iterative development across multiple indications, enabling each clinical study to inform the next generation of product design.

In autoimmune disease, CREATE’s lead program CRT-402 is a next-generation CD19-targeted in vivo CAR-T therapy designed to enable deep and durable B-cell depletion. Preclinical data in non-human primates have shown robust B-cell depletion, while the platform’s repeat-dosing potential may support immune reset strategies in autoimmune disorders. CREATE is also advancing a dual CAR CD19 x BCMA-directed therapy, which could broaden its reach across refractory autoimmune indications by targeting both B cells and plasma cells.

In oncology, CREATE continues to develop in vivo immune programming therapies for areas of high unmet need. The company highlighted early clinical data from its MT-303 program in frontline hepatocellular carcinoma, describing the response profile as highly compelling. Together, the autoimmune and oncology programs reflect CREATE’s broader strategy of combining clinically validated CAR architectures, optimized RNA design, targeted delivery technologies, and internal manufacturing capabilities.

As part of the financing, Ron Philip has joined CREATE as Executive Chairman. Brian Cuneo of ARCH Venture Partners and Tom Thomas, PhD, of Newpath Partners have also joined the company’s Board of Directors. These leadership and board additions are intended to support CREATE’s next phase of clinical growth and platform expansion.

The financing highlights continued investor interest in in vivo cell therapy, a field aiming to simplify immune cell engineering by shifting programming from the laboratory into the patient’s body. If successfully translated, repeat-dose mRNA-LNP immune programming could reshape how engineered immune therapies are developed, manufactured, and delivered for autoimmune disease and cancer.